Diamyd Medical Stock: price and insider trades · Sweden
No insider purchase over the last 90 days. The latest, by Mark Atkinson, was filed 21 Sept 2020.
Diamyd Medical: what insiders have been doing
Diamyd Medical is a listed company. Its insiders report their share dealings to Finansinspektionen. The past year has been quiet: not a single insider filing for Diamyd Medical. The previous disclosure was published on 21 September 2020.
Our records for Diamyd Medical go back to 2017, with 2 purchases and no sales on the open market in total.
Elsewhere in the same market, our signals recently picked up insider purchases at Linc AB and Dynavox Group AB. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.
Financial data
· cache
- 6,750 shares@ US$4.56100.0% of flowAktieISIN SE0005162880FI:csv-eda153c380117dfe8aa1Canonical exit: 12 Nov 2020 (T+90)
- 21,332 shares@ SEK 3.50100.0% of flowFI:csv-511fe35b4925199cfce8Canonical exit: 21 Aug 2017 (T+90)
2 of 2 declarations
About Diamyd Medical
Diamyd Medical is a Swedish biopharmaceutical company focused on developing treatments for type 1 diabetes. It specializes in innovative therapies based on the GAD65 antigen protein.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations